These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 16033851

  • 1. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
    Clin Cancer Res; 2005 Jul 15; 11(14):5319-28. PubMed ID: 16033851
    [Abstract] [Full Text] [Related]

  • 2. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA, Lebwohl D.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [Abstract] [Full Text] [Related]

  • 3. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J, Pornon A, Chen B, Chen S, Evans DB.
    Breast Cancer Res; 2008 Apr 15; 10(4):R56. PubMed ID: 18611244
    [Abstract] [Full Text] [Related]

  • 4. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 01; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 6. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 7. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ.
    Neuroendocrinology; 2007 Sep 01; 85(1):54-60. PubMed ID: 17310129
    [Abstract] [Full Text] [Related]

  • 8. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 01; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 9. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 01; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 10. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 11. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O, Wackwitz B, Haus U, Ortmann O.
    Gynecol Oncol; 2006 Aug 05; 102(2):292-9. PubMed ID: 16443261
    [Abstract] [Full Text] [Related]

  • 12. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 05; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 14. Letrozole sensitizes breast cancer cells to ionizing radiation.
    Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A.
    Breast Cancer Res; 2005 Mar 01; 7(1):R156-63. PubMed ID: 15642164
    [Abstract] [Full Text] [Related]

  • 15. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
    Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A.
    Cancer Res; 2006 Aug 01; 66(15):7775-82. PubMed ID: 16885381
    [Abstract] [Full Text] [Related]

  • 16. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, Groh N, Polier A, Brandt I, Lotz L, Hoffmann I, Koppitz F, Oeser S, Mueller A, Fasching PA, Lux MP, Beckmann MW, Schrauder MG.
    Biochem Pharmacol; 2012 Feb 15; 83(4):480-8. PubMed ID: 22142888
    [Abstract] [Full Text] [Related]

  • 17. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K, Lykkesfeldt AE.
    J Steroid Biochem Mol Biol; 2005 Jan 15; 93(1):25-34. PubMed ID: 15748829
    [Abstract] [Full Text] [Related]

  • 18. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A, Dalino P, Salahuddin N, Korbonits M, Grossman AB.
    Neuroendocrinology; 2008 Jan 15; 87(3):168-81. PubMed ID: 18025810
    [Abstract] [Full Text] [Related]

  • 19. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):892-900. PubMed ID: 18245553
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM, Mateo-Lozano S, Notario V.
    Oncogene; 2005 May 05; 24(20):3348-57. PubMed ID: 15782132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.